<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Stem Cell Reports</journal-id><journal-id journal-id-type="iso-abbrev">Stem Cell Reports</journal-id><journal-title-group><journal-title>Stem Cell Reports</journal-title></journal-title-group><issn pub-type="epub">2213-6711</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39824186</article-id><article-id pub-id-type="pmc">PMC11864152</article-id><article-id pub-id-type="pii">S2213-6711(24)00351-5</article-id><article-id pub-id-type="doi">10.1016/j.stemcr.2024.102391</article-id><article-id pub-id-type="publisher-id">102391</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Selective activation of FZD2 and FZD7 reveals non-redundant function during mesoderm differentiation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Chidiac</surname><given-names>Rony</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Yang</surname><given-names>Andy</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Kubarakos</surname><given-names>Elli</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Mikolajewicz</surname><given-names>Nicholas</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Han</surname><given-names>Hong</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Almeida</surname><given-names>Maira P.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Thibeault</surname><given-names>Pierre E.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Lin</surname><given-names>Sichun</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>MacLeod</surname><given-names>Graham</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Gratton</surname><given-names>Jean-Philippe</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Moffat</surname><given-names>Jason</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Angers</surname><given-names>Stephane</given-names></name><email>stephane.angers@utoronto.ca</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="fn1" ref-type="fn">7</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada</aff><aff id="aff2"><label>2</label>Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada</aff><aff id="aff3"><label>3</label>Program in Genetics and Genome Biology, The Hospital for Sick Kids, Toronto, ON, Canada</aff><aff id="aff4"><label>4</label>Department of Pharmacology and Physiology, Faculty of Medicine, Universit&#x000e9; de Montr&#x000e9;al, Montreal, QC, Canada</aff><aff id="aff5"><label>5</label>Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada</aff><aff id="aff6"><label>6</label>Department of Biochemistry, University of Toronto, Toronto, ON, Canada</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>stephane.angers@utoronto.ca</email></corresp><fn id="fn1"><label>7</label><p id="ntpara0010">Lead contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>16</day><month>1</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>11</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2025</year></pub-date><volume>20</volume><issue>2</issue><elocation-id>102391</elocation-id><history><date date-type="received"><day>6</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Author(s)</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>During gastrulation, Wnt-&#x003b2;-catenin signaling dictates lineage bifurcation generating different mesoderm cell types. However, the specific role of Wnt receptors in mesoderm specification remains elusive. Using selective Frizzled (FZD) and LRP5/6 antibody-based agonists, we examined FZD receptors&#x02019; function during directed mesoderm differentiation of human pluripotent stem cells (hPSCs). We found that FZD2 and FZD7 receptors are expressed at the membrane of hPSCs and that their activation triggers &#x003b2;-catenin signaling with different kinetics, thereby influencing mesoderm patterning choices. Specifically, FZD7 activation enhances both paraxial and lateral mesoderm differentiation, whereas FZD2 activation favors paraxial mesoderm. Mechanistically, FZD2 activation promotes sustained Wnt-&#x003b2;-catenin levels, guiding hPSCs differentiation toward paraxial mesoderm, while blocking lateral mesoderm. In contrast, FZD7 activation kinetics display similar initial activation but more dampening of &#x003b2;-catenin signaling, permitting lateral mesoderm induction in addition to paraxial mesoderm specification. Our findings reveal non-redundant roles for FZD2 and FZD7 in mesoderm specification, offering leverage for precise directed differentiation outcomes.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">FZD2 and FZD7 are the most highly expressed FZD receptors in hPSCs</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">FZD7 but not FZD2 activation directs lateral mesoderm differentiation</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">FZD2 and FZD7 activation trigger distinct Wnt-&#x003b2;-catenin signaling kinetics</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Selective activation of FZD2 and FZD7 activation dictates the mesodermal fate</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p>Chidiac and colleagues characterize Wnt receptor roles in mesoderm specification. They showed that the activation of FZD2 and FZD7, the only receptors expressed at the hPSC membrane, drives &#x003b2;-catenin signaling with unique kinetics. FZD7 activation is transient promoting paraxial and lateral mesoderm, while FZD2 activation is sustained favoring paraxial mesoderm. These findings underscore their distinct, non-redundant roles in mesoderm patterning.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Wnt signaling</kwd><kwd>human pluripotent stem cells</kwd><kwd>mesoderm specification</kwd><kwd>directed differentiation</kwd><kwd>Wnt agonists</kwd><kwd>Frizzled receptors</kwd></kwd-group></article-meta><notes><p id="misc0010">Published: January 16, 2025</p></notes></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">During embryonic development, secreted growth factors govern the differentiation of human pluripotent stem cells (hPSCs) into specific cell types (<xref rid="bib11" ref-type="bibr">Fowler et&#x000a0;al., 2020</xref>). The magnitude and duration of intracellular signaling determine cell fate commitment. hPSCs are a tractable <italic>in&#x000a0;vitro</italic> model to study how these signals influence cell differentiation. However, current protocols often result in heterogeneous cell types, limiting their therapeutic potential (<xref rid="bib9" ref-type="bibr">Cohen and Melton, 2011</xref>; <xref rid="bib11" ref-type="bibr">Fowler et&#x000a0;al., 2020</xref>). A refined understanding of the signaling mechanisms underlying cellular differentiation will lead to more homogenous and functional cell populations.</p><p id="p0035">During gastrulation, hPSCs differentiate into three germ layers (<xref rid="bib35" ref-type="bibr">Solnica-Krezel and Sepich, 2012</xref>), a process initiated by the formation of a primitive streak (PS), coinciding with the expression of the early pan-mesodermal marker gene, <italic>TBXT</italic> (encoding the BRACHYURY protein) (<xref rid="bib18" ref-type="bibr">Kispert and Herrmann, 1994</xref>; <xref rid="bib24" ref-type="bibr">Murry and Keller, 2008</xref>). Different anterior-posterior regions of the PS generate distinct mesodermal derivatives <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> (<xref rid="bib11" ref-type="bibr">Fowler et&#x000a0;al., 2020</xref>). Current mesoderm differentiation protocols use a combination of bone morphogenetic protein 4 (BMP4), fibroblast growth factor 2 (FGF2), Activin-A/NODAL, and Wnt signaling (<xref rid="bib1" ref-type="bibr">Ang et&#x000a0;al., 2022</xref>; <xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>). NODAL and BMP4 signaling gradients establish the anterior-posterior axis of the PS whereas FGF and Wnt signaling are active throughout the PS at all stages (<xref rid="bib16" ref-type="bibr">Kattman et&#x000a0;al., 2011</xref>; <xref rid="bib20" ref-type="bibr">Loh et&#x000a0;al., 2014</xref>; <xref rid="bib38" ref-type="bibr">Sumi et&#x000a0;al., 2008</xref>). Wnt-&#x003b2;-catenin signaling is known to modulate the differentiation of hPSCs (<xref rid="bib7" ref-type="bibr">Chidiac and Angers, 2023</xref>). Wnt proteins are required to differentiate hPSCs into mesendoderm since inhibition of Wnt-&#x003b2;-catenin signaling blocks PS induction and any downstream derivatives (<xref rid="bib30" ref-type="bibr">Rao et&#x000a0;al., 2016</xref>). After the formation of the PS, sustained BMP4 signaling activation and Wnt signaling suppression promote the development of lateral mesoderm (<xref rid="bib1" ref-type="bibr">Ang et&#x000a0;al., 2022</xref>; <xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>; <xref rid="bib30" ref-type="bibr">Rao et&#x000a0;al., 2016</xref>). In contrast, prolonged Wnt signaling activation leads to the formation of the paraxial mesoderm (<xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>; <xref rid="bib40" ref-type="bibr">Tani et&#x000a0;al., 2020</xref>). The paraxial mesoderm gives rise to somites that produce the bone, cartilage, skeletal muscle, and dorsal dermis whereas lateral mesoderm generates limb bud mesoderm, cardiac mesoderm, and blood (<xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>).</p><p id="p0040">Wnt-&#x003b2;-catenin signaling is initiated upon Wnt ligands binding to Frizzled (FZD) receptors and low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) resulting in the accumulation and nuclear translocation of &#x003b2;-catenin (<xref rid="bib36" ref-type="bibr">Steinhart and Angers, 2018</xref>). In stem and progenitor cells, nuclear &#x003b2;-catenin regulates a broad spectrum of context-dependent Wnt target genes implicated in cell fate specification and differentiation (<xref rid="bib4" ref-type="bibr">Chalamalasetty et&#x000a0;al., 2011</xref>; <xref rid="bib14" ref-type="bibr">Huggins et&#x000a0;al., 2017</xref>; <xref rid="bib45" ref-type="bibr">Yamaguchi et&#x000a0;al., 1999</xref>). In vertebrates, 19 Wnt ligands can bind and activate 10 different FZDs and LRP5/6 co-receptors (<xref rid="bib36" ref-type="bibr">Steinhart and Angers, 2018</xref>). The function of individual FZDs during the differentiation of hPSCs remains unknown due to a paucity of available reagents to study the expression and selective activation of individual FZD receptors. Most hPSC-directed differentiation protocols often use glycogen synthase kinase-3 &#x003b1;/&#x003b2; inhibitors (GSK3i; e.g., CHIR99021) to activate Wnt-&#x003b2;-catenin signaling (<xref rid="bib39" ref-type="bibr">Tan et&#x000a0;al., 2013</xref>); however, the pleiotropic roles of this kinase could lead to off-target effects. Recent protein engineering advances have enabled the development of antibody-based FZD and LRP5/6 agonists (FLAgs) that can cluster and activate one or multiple FZDs and LRP co-receptors with complete specificity and high efficiency (<xref rid="bib5" ref-type="bibr">Chen et&#x000a0;al., 2020</xref>; <xref rid="bib15" ref-type="bibr">Janda et&#x000a0;al., 2017</xref>; <xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>).</p><p id="p0045">Here, we used tetravalent FLAg antibodies (<xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>) to precisely dissect the dynamics of Wnt-FZD signaling circuits in individual progenitor cells during mesoderm specification. We found that both FZD2 and FZD7 are expressed in hPSCs but differences in &#x003b2;-catenin activation kinetics triggered by FZD2 and FZD7 lead to distinct gene expression programs that affect the mesoderm differentiation outcome. Whereas activation of FZD7 promotes paraxial and lateral mesoderm formation, FZD2 stimulation preferentially induces paraxial mesoderm specification. Our results show that FZD2 activation leads to longer and sustained Wnt-&#x003b2;-catenin activation when compared to FZD7 activation. These findings demonstrate that individual FZD receptors activate Wnt-&#x003b2;-catenin signaling with different kinetics thereby influencing cell lineage commitment during the differentiation of hPSCs into mesoderm.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>FZD2 and FZD7 receptors are required for Wnt signaling during PS induction</title><p id="p0050">To examine Wnt signaling activity in hPSCs, we generated an H1 iCas9 <italic>AXIN2</italic>-Citrine reporter human embryonic stem cell (hESC) line by replacing the first exon of <italic>AXIN2</italic> (a generic Wnt-&#x003b2;-catenin target gene) with a cDNA coding for histone H2B fused to the Citrine fluorescent protein into H1 hESCs that were previously engineered to express doxycycline-inducible Cas9 (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>A). Upon clonal selection and expansion, cells maintained expression of pluripotency markers such as OCT4 and SOX2 (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>B). Validating the reporter line, treatment with the GSK3i CHIR99021 led to a significant increase in Citrine intensity and BRACHYURY expression confirming the activation of Wnt-&#x003b2;-catenin signaling and induction of the PS, respectively (<xref rid="mmc1" ref-type="supplementary-material">Figures&#x000a0;S1</xref>C and S1D).</p><p id="p0055">To identify regulators of Wnt-&#x003b2;-catenin signaling during PS formation, we performed a genome-wide CRISPR screen in the reporter H1 line treated with CHIR99021 to induce PS fate (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). To do this, cells were first transduced with the human Toronto KnockOut library version 3 (TKOv3), selected with puromycin, and then Cas9 expression&#x000a0;was induced to generate a population of knockout (KO) cells. Subsequently, cells were treated with CHIR99021 for three days and sorted to isolate the top and bottom 15% citrine-expressing cells (higher and lower amounts of &#x003b2;-catenin signaling, respectively). Next-generation sequencing was performed to quantify the relative single guide RNA (sgRNA) abundance in these two fractions (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref>A and 1B; <xref rid="mmc2" ref-type="supplementary-material">Table&#x000a0;S1</xref>). Multiple known negative regulators of Wnt-&#x003b2;-catenin signaling such as <italic>TCF7L2</italic>, <italic>AXIN1</italic>, <italic>ZNRF3</italic>, and <italic>GSK3B</italic> and positive regulators, such as <italic>LRP6</italic>, <italic>DVL2</italic>, <italic>CTNNB1</italic>, <italic>BCL9L</italic>, <italic>FZD2</italic>, and <italic>FZD7</italic>, were significantly enriched in the screen (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>E). Supporting these results, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment showed that Wnt signaling was among the top five enriched pathways (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>F). The inhibition of GSK3&#x003b1;/&#x003b2; using CHIR99021 initiates Wnt signaling downstream of FZD receptors, yet two (FZD2 and FZD7) of the ten human FZD receptors were identified as positive regulators of Wnt signaling during hESCs differentiation toward PS indicating a putative contribution of Wnt proteins-mediated signaling under these conditions (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B). To validate the screen hits, we knocked out <italic>FZD2</italic>, <italic>FZD7</italic>, and <italic>CTNNB1</italic> using independent sgRNAs and observed a reduction in Citrine levels three days post-CHIR99021 treatment (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>G).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>FZD2 and FZD7 are required for Wnt activation and primitive streak induction in hESCs</p><p>(A) Schematic representing a genome-wide CRISPR-Cas9 in H1 <italic>AXIN2</italic>-citrine reporter cell line treated with CHIR99021 for three days.</p><p>(B) Volcano plot of gene enrichment in the top versus bottom 15% fractions from the CRISPR screen (cutoff; log2 fold change above&#x000a0;+/&#x02212; 0.5, &#x02212;log10 FDR &#x0003c;0.1). Green and red dots correspond to significantly enriched negative and positive regulators, respectively. Table&#x000a0;lists the top 10 hits. Highlighted dots represent selected Wnt-related hits.</p><p>(C) FZDs expression profiling in H1 hESCs by flow cytometry using specific FZDs IgG antibodies (<italic>n</italic>&#x000a0;= 4&#x02013;6 independent experiments).</p><p>(D) Co-expression of FZD2 and FZD7 in H1 hESCs. Representative plots of three independent experiments.</p><p>(E) Dose-response curve for the activation of LEF/TCF reporter gene in HEK293T cells treated with F2L6.13 or F7L6.13 (<italic>n</italic>&#x000a0;= 2 independent experiments).</p><p>(F) (Left) Flow cytometry analysis of the percentage of AXIN2-positive cells after one day of treatment with 30&#x000a0;nM of F2L6.13 or F7L6.13 using the H1 <italic>AXIN2</italic>-citrine reporter line (<italic>n</italic>&#x000a0;= 3 independent experiments). (Right) RT-qPCR of <italic>SP5</italic> mRNA expression in H1 hESC treated with 30&#x000a0;nM of F2L6.13 and F7L6.13 for 24&#x000a0;h (<italic>n</italic>&#x000a0;= 4 independent experiments).</p><p>(G) RT-qPCR of <italic>SP5</italic> mRNA expression in H1 hESC treated with 30&#x000a0;nM of F2L6.13 and F7L6.13 for 24&#x000a0;h in FZD2 and FZD7 KO hESC lines (<italic>n</italic>&#x000a0;= 3 independent experiments).</p><p>Data are represented as mean&#x000a0;&#x000b1; SEM. Statistical analysis was performed using a two-tailed t test or one-way ANOVA followed by Tukey&#x02019;s <italic>post hoc</italic> test. <sup>&#x02217;</sup><italic>p</italic> &#x02264; 0.05 was considered significant.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0060">Next, we investigated the cell surface expression of different FZDs using antibodies that were designed to specifically bind to each of the 10 FZD receptors (<xref rid="bib29" ref-type="bibr">Pavlovic et&#x000a0;al., 2018</xref>; <xref rid="bib37" ref-type="bibr">Steinhart et&#x000a0;al., 2017</xref>). We found that FZD2 and FZD7 were highly expressed at the cell membrane of hPSCs in both H1 and WTC11 lines (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref>C, 1D, and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>H). Overall, these results suggest that the two main FZD receptors expressed in hPSCs, FZD2 and FZD7, have non-redundant functions during Wnt activation in hPSCs and PS formation.</p></sec><sec id="sec2.2"><title>Antibody agonists specifically bind and activate FZD2 and FZD7 receptors in hESCs</title><p id="p0065">We recently introduced a novel antibody modality platform enabling the selective activation of one or more FZD and LRP5/6 receptors (<xref rid="bib8" ref-type="bibr">Chidiac et&#x000a0;al., 2021</xref>; <xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>). These FLAgs fully mimic the function of Wnt proteins both <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> (<xref rid="bib8" ref-type="bibr">Chidiac et&#x000a0;al., 2021</xref>; <xref rid="bib13" ref-type="bibr">Hu&#x000a0;et&#x000a0;al., 2022</xref>; <xref rid="bib25" ref-type="bibr">Nabhan et&#x000a0;al., 2023</xref>; <xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>; <xref rid="bib46" ref-type="bibr">Yang et&#x000a0;al., 2024</xref>). Leveraging this platform, we first compared FLAgs targeting the FZD2:LRP6 (F2L6.13) and FZD7:LRP6 (F7L6.13) receptor complexes (<xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>) for their ability to activate &#x003b2;-catenin signaling. Treatment of HEK293T cells expressing the &#x003b2;-catenin-activated reporter&#x000a0;(pBAR) (<xref rid="bib2" ref-type="bibr">Biechele and Moon, 2008</xref>), which monitors lymphoid enhancer factor/T cell factor (LEF/TCF)-mediated transcription, showed that F2L6.13 (half maximal effective concentration (EC50)&#x000a0;= 0.12&#x000a0;nM) is more potent than F7L6.13 (EC50&#x000a0;= 10.79&#x000a0;nM) (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E). To&#x000a0;study the role of FZD2 and FZD7 in hPSC differentiation, we used 30&#x000a0;nM of F2L6.13 and F7L6.13 since near-maximal levels of Wnt-&#x003b2;-catenin signaling were observed at this dose (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E). As expected, treatment of H1 hESCs with 30&#x000a0;nM of F2L6.13 and F7L6.13 for 24&#x000a0;h increased <italic>SP5</italic> mRNA levels and AXIN2-Citrine expression to comparable levels (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>F). To confirm the specificity of the agonists, we used CRISPR-Cas9 gene editing to generate clonal FZD2 and/or FZD7 KOs in H1 cells and confirmed the KO efficiency by sequencing (data not shown) and flow cytometry (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>I). These KO clones remain pluripotent as shown by the retention of OCT4 expression (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>J). Confirming the specificity of the antibody agonists, F2L6.13- or F7L6.13-mediated activation of &#x003b2;-catenin signaling was blunted in FZD2 and FZD7 KO lines, respectively (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G). Deletion of each individual FZD did not affect the expression or the activity of the other receptor (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref>G and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>I). We conclude that F2L6.13 and F7L6.13 specifically and efficiently activate &#x003b2;-catenin signaling in hPSCs through the respective engagement of FZD2:LRP6 and FZD7:LRP6 receptor complexes.</p></sec><sec id="sec2.3"><title>Activation of FZD7 but not FZD2 receptor induces lateral mesoderm</title><p id="p0070">Previously published differentiation protocols used Activin-A, BMP4, FGF2, and a GSK3i such as CHIR99021 to induce PS formation and subsequent specification of cells into different mesodermal subtypes (<xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>). To study the role of FZD2 and FZD7 during mesoderm differentiation, we replaced CHIR99021 with (1) a FLAg that binds to FZD1, 2, 4, 5, 7, and 8 (PanFLAg); (2) F2L6.13; or (3) F7L6.13 during differentiation (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A). Similar to CHIR99021 treatment, the addition of each FLAg induced PS formation as shown by increased BRACHYURY expression and reduction of OCT4 and SOX2 after one day of differentiation (<xref rid="mmc1" ref-type="supplementary-material">Figures&#x000a0;S2</xref>A&#x02013;S2C). We next monitored mesoderm specification under conditions where CHIR99021 was substituted by F2L6.13 or F7L6.13 treatments using a panel of paraxial and lateral mesoderm markers. Interestingly, when normalized to the absence of Wnt activation (No Wnt condition), F2L6.13 significantly increased paraxial mesoderm markers <italic>TBX6</italic> and <italic>MSGN1</italic> but not lateral/cardiac mesoderm markers <italic>HAND1</italic> and <italic>ISL1</italic> (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref>B, 2C, and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>D). On the other hand, PanFLAg and F7L6.13 treatment increased both paraxial and lateral mesoderm markers (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref>B, 2C, and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>D). This result suggests that, although early activation of FZD2 and FZD7 receptors can induce Wnt/&#x003b2;-catenin signaling and PS formation, subsequent activation of these two FZD receptor complexes leads to distinct mesodermal cell fates. Since only treatment with F7L6.13 promoted lateral mesoderm specification, we predicted that F2L6.13 would be unable to support cardiac mesoderm differentiation and cardiomyocyte production. As expected, F7L6.13&#x02014;but not F2L6.13&#x02014;treatment increased cardiac mesoderm and cardiomyocyte formation above the &#x0201c;No Wnt&#x0201d; control condition, as shown by an increase in NKX2.5 and cardiac troponin (cTnT) expression, respectively (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref>D and 2E). We conclude that, while stimulation of FZD7 leads to both paraxial and lateral mesoderm fate specification, FZD2 activation preferentially promotes paraxial mesoderm differentiation.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>FZD2 and FZD7 activation promote distinct bifurcation choices into paraxial or lateral mesoderm</p><p>(A) Paraxial versus lateral mesoderm differentiation protocol adapted from <xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>. In each differentiation protocol, CHIR99021 treatment was replaced by 30&#x000a0;nM of isotype control, PanFLAg, F2L6.13, or F7L6.13 treatment.</p><p>(B) RT-qPCR of hESC-derived paraxial mesoderm markers (<italic>TBX6</italic> and <italic>MSGN1</italic>) or lateral mesoderm markers (<italic>HAND1</italic> and <italic>ISL1</italic>) at day 2 of differentiation (<italic>n</italic>&#x000a0;= 4&#x02013;5 independent differentiation experiments).</p><p>(C) TBX6 (green) and HAND1 (red) immunostaining staining in paraxial versus lateral mesoderm differentiation protocol in H1 hESCs. Images are representative of three independent differentiation experiments.</p><p>(D) NKX2.5 immunostaining staining (left) and flow cytometry quantification of NKX2.5 expression (right) of hESC-derived cardiac mesoderm (day 4) (<italic>n</italic>&#x000a0;= 3 independent differentiation experiments). Images are representative of three independent differentiation experiments.</p><p>(E) cTnT immunostaining staining (left) and image quantification (right) of hESC-derived cardiomyocytes (day 8) (<italic>n</italic>&#x000a0;= 3 independent differentiation experiments). Images are representative of three independent differentiation experiments.</p><p>Data are represented as mean&#x000a0;&#x000b1; SEM. Statistical analysis was performed using a one-way ANOVA followed by Tukey&#x02019;s <italic>post hoc</italic> test. <sup>&#x02217;</sup><italic>p</italic> &#x02264; 0.05 was considered significant.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0075">To probe mechanisms and eliminate confounding effects, we assessed whether &#x003b2;-catenin activation using FLAg, Wnt proteins, or CHIR99021 treatments was sufficient to induce mesoderm specification independently of exogenous FGF2, ACTIVIN, and BMP4 growth factors. To do this, we treated H1 hESC with CHIR99021 (3&#x000a0;&#x003bc;M or 6&#x000a0;&#x003bc;M), rWnt3a purified protein (300&#x000a0;ng/mL), PanFLAg, F2L6.13, or F7L6.13 (30&#x000a0;nM) alone, in the absence of any exogenous factors used in standard mesoderm differentiation protocols (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). After 4&#x000a0;days of PanFLAg, F2L6.13, or F7L6.13 treatment alone, we observed an increase in BRACHYURY expression to levels comparable to&#x000a0;or higher than those after treatment with 6&#x000a0;&#x003bc;M CHIR99021 that was accompanied by a significant decrease of self-renewal markers OCT4 and SOX2 (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>A&#x02013;S3E). FZD4 and FZD5 receptors are not expressed in hPSCs, and therefore F4L6.13 and F5L6.13 (antibodies previously shown to activate &#x003b2;-catenin signaling through FZD4 and FZD5 receptors, respectively [<xref rid="bib8" ref-type="bibr">Chidiac et&#x000a0;al., 2021</xref>; <xref rid="bib46" ref-type="bibr">Yang et&#x000a0;al., 2024</xref>]) were used as negative controls. We found that stimulation of hPSCs with F2L6.13 or F7L6.13 was sufficient to induce PS (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>B and 3C). We then asked if F2L6.13 or F7L6.13 treatment can derive&#x000a0;specific mesoderm subtypes. Treating with 3&#x000a0;&#x003bc;M of CHIR99021 or 300&#x000a0;ng/mL of purified Wnt3a protein alone increased BRACHYURY expression slightly but did not induce any mesoderm specification as shown by the absence of induction of paraxial (<italic>TBX6</italic> and <italic>MSGN1</italic>) and lateral (<italic>HAND1</italic> and <italic>ISL1</italic>) mesoderm markers (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>A&#x02013;3F and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>A). This suggests that lower levels of &#x003b2;-catenin signaling can lead to PS but are not sufficient to generate mesoderm subtypes. Indeed, when cells were treated with higher doses (6&#x000a0;&#x003bc;M) of CHIR99021, an increase in paraxial and lateral mesoderm markers was observed. Notably, we found that treating hPSCs with 30&#x000a0;nM of F2L6.13 for 4&#x000a0;days significantly increased paraxial mesoderm markers expression (<italic>TBX6</italic> and <italic>MSGN1</italic>) but did not induce lateral mesoderm markers expression (<italic>HAND1</italic> and <italic>ISL1</italic>) (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>D&#x02013;3F). In contrast, PanFLAg and F7L6.13 treatment significantly increased the expression of both lateral and paraxial mesoderm markers (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3</xref>D&#x02013;3F). PS is known to form definitive endoderm and mesoderm. In the absence of other signaling cues used in directed differentiation protocols, F2L6.13 and F7L6.13 treatment also increased SOX17 (endoderm marker) indicating the formation of a heterogeneous mesendoderm population (<xref rid="mmc1" ref-type="supplementary-material">Figures&#x000a0;S3</xref>C and S3E). Overall, these results suggest that FZD2 activation drives hPSCs differentiation only toward paraxial mesoderm, whereas FZD7 activation promotes the formation of paraxial and lateral mesoderm.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>F2L6.13 and F7L6.13 differentially alter the transcriptome of hESCs</p><p>(A) Schematic for mesoderm (ME) differentiation following treatment of hESCs with FLAgs or CHIR99021 without any other external signaling cues.</p><p>(B and C) Immunostaining (B)&#x000a0;and RT-qPCR (C)&#x000a0;of the primitive streak (<italic>TBXT</italic>) and pluripotency (<italic>OCT4</italic>) markers after 4&#x000a0;days of treatment with the indicated doses of CHIR99021 or 30&#x000a0;nM of different FLAgs (<italic>n</italic>&#x000a0;= 4 independent differentiation experiments). Images in (B)&#x000a0;are representative of three independent differentiation experiments.</p><p>(D and E) RT-qPCR of H1 hESC-derived paraxial mesoderm (<italic>TBX6</italic> and <italic>MSGN1</italic>) (D)&#x000a0;and lateral mesoderm (<italic>HAND1</italic> and <italic>ISL1</italic>) (E)&#x000a0;markers after 4&#x000a0;days of treatment with the indicated doses of CHIR99021 or 30&#x000a0;nM of different FLAgs (<italic>n</italic>&#x000a0;= 3&#x02013;4 independent differentiation experiments).</p><p>(F) Immunostaining of TBX6 and HAND1 in CHIR99021-, PanFLAg-, F2L6.13-, or F7L6.13-treated H1 hESCs. Images are representative of three independent differentiation experiments.</p><p>(G) (Left) Principal-component analysis of RNA sequencing comparing F2L6.13 and F7L6.13 treatment to the standard differentiation protocol in which CHIR99021 treatment was used to drive specifically paraxial or lateral mesoderm. (Right) Top 10 genes defining PC1 and PC2 were listed. Lateral mesoderm markers were highlighted in red. For RNA sequencing, three independent differentiation experiments per condition were performed.</p><p>(H) Heatmap of hierarchical clustering of paraxial and lateral mesoderm makers.</p><p>(I) Volcano plot of gene enrichment in F2L6.13- versus F7L6.13-treated H1 hESCs (30&#x000a0;nM, 4&#x000a0;days). F2L6.13-enriched genes (red circles) and F7L6.13-enriched genes (blue circles) were highlighted.</p><p>(J) GSEA enrichment analysis shows NODAL and BMP4 gene sets enriched in F2L6.13 and F7L6.13 treatment, respectively.</p><p>Data are represented as mean&#x000a0;&#x000b1; SEM. Statistical analysis was performed using a one-way ANOVA followed by Tukey&#x02019;s <italic>post hoc</italic> test. <sup>&#x02217;</sup><italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.05 was considered significant.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.4"><title>Bifurcation of paraxial versus lateral mesoderm using F2L6.13 and F7L6.13 treatment</title><p id="p0080">To understand the mesodermal lineage differentiation bias between the two selective FLAgs targeting FZD2 and FZD7 receptors, we performed bulk RNA sequencing in H1 hESCs treated with either F2L6.13 or F7L6.13 for 4&#x000a0;days. We compared these treatments to the standard protocols used to derive paraxial or lateral mesoderm. Principal-component analysis (PCA) showed clustering of the F7L6.13-treated population with the lateral mesoderm protocol (CHIR_Lateral) and the F2L6.13-treated population with the paraxial mesoderm protocol (CHIR_Paraxial) on the principal component 2 (PC2) axis (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G). Genes involved in lateral mesoderm formation (e.g., <italic>GATA2</italic>, <italic>GATA3</italic>, <italic>ISL1</italic>, and <italic>HAND1</italic>) were among the top 10 genes contributing to the variance explained by PC2 (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G), further confirming that PC2 represents the paraxial-lateral mesoderm axis of variation. Using a curated list of paraxial and lateral mesoderm markers, we found that F7L6.13 treatment induced both mesoderm progenitor lineages whereas F2L6.13 preferentially promoted paraxial mesoderm (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>H). We next performed differential gene expression analysis comparing F2L6.13 and F7L6.13 treatments (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>I and <xref rid="mmc3" ref-type="supplementary-material">Table&#x000a0;S2</xref>). Paraxial mesoderm genes were not differentially regulated reflecting that both treatments increase paraxial mesoderm markers. However, lateral/cardiac mesoderm genes (e.g., <italic>HAND1</italic>, <italic>ISL1</italic>, and <italic>NKX2.5</italic>) were significantly enriched in the F7L6.13 treatment. Interestingly, <italic>BMP4</italic> expression was significantly increased with F7L6.13 treatment and <italic>NODAL</italic>, <italic>LEFTY1</italic>, and <italic>CER1</italic> were significantly upregulated with F2L6.13 treatment. These genes are known to play different/opposing roles in cell fate specification during PS formation (<xref rid="bib16" ref-type="bibr">Kattman et&#x000a0;al., 2011</xref>; <xref rid="bib27" ref-type="bibr">Nostro et&#x000a0;al., 2008</xref>; <xref rid="bib38" ref-type="bibr">Sumi et&#x000a0;al., 2008</xref>; <xref rid="bib44" ref-type="bibr">Xu et&#x000a0;al., 2014</xref>). For instance, BMP4 plays an important role in posteriorizing and lateral mesoderm formation and NODAL is increased during anterior cell&#x000a0;specification (<xref rid="bib22" ref-type="bibr">Martyn et&#x000a0;al., 2018</xref>; <xref rid="bib42" ref-type="bibr">Tsaytler et&#x000a0;al., 2023</xref>). Accordingly, gene set enrichment analysis (GSEA) comparing the transcriptome of the two treatments revealed that BMP4 signaling was enriched in the F7L6.13-treated cells whereas NODAL signaling was enriched in the F2L7.13-treated cells (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>J). Using qPCR, we validated that <italic>BMP4</italic> mRNA levels were highly upregulated following F7L6.13&#x02014;but not F2L6.13&#x02014;treatment. BMP4 signaling inhibition using LDN193189 significantly reduced the potency of F7L6.13 in deriving lateral mesoderm (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>F). These results suggest that F7L6.13 mediates lateral mesoderm differentiation in part through the activation of BMP4 signaling.</p></sec><sec id="sec2.5"><title>snRNA-seq reveals temporal differentiation dynamics in response to F2L6.13 and F7L6.13 treatment</title><p id="p0085">We next used single-nucleus RNA sequencing (snRNA-seq; sci-RNA-seq3 protocol) to profile the temporal transcriptomic changes and differentiation kinetics of F2L6.13- and F7L6.13-treated H1 hESCs during days 2&#x02013;5 of mesoderm induction. After stringent quality control, filtering and batch-effect correction, 81,294 nuclei were included for downstream analysis with a median of 2,097 genes detected per nucleus. We identified 16 distinct cell clusters, representing subpopulations of stem cells (S1-2), PS (Ps<sub>1</sub>1-3 and Ps<sub>2</sub>1), paraxial (Pm<sub>1</sub>1-3 and Pm<sub>2</sub>1-2) and lateral (Lm1-3) mesoderm, and endoderm (E1-2) (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>A and <xref rid="mmc1" ref-type="supplementary-material">S4</xref>A). Cell-type annotations were based on cell-type marker profiles (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S4</xref>B) and reference atlas-based transfer learning (see <xref rid="mmc1" ref-type="supplementary-material">supplemental experimental procedures</xref>). Each temporal dynamic class was dissected to ensure cell-type compositions were well resolved. In line with our previous data, F7L6.13 but not F2L6.13 treatment induced increased lateral mesoderm markers <italic>HAND1</italic>, while F2L6.13 treatment increased endoderm markers <italic>SOX17</italic> and <italic>FOXA2</italic> (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). We also performed differential expression analyses based on the time-dependent relative abundance similarities of each cluster and their lineage relationships (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>D&#x02013;4F). As expected, the abundance of stem cell states decreased over time as shown by pluripotency markers such as <italic>SOX2</italic> and <italic>PTPRZ1</italic>, whereas mesodermal and endodermal progenitors expressing specific markers such as <italic>TBX6</italic>, <italic>MSGN1</italic>, <italic>HAND1</italic>, and <italic>SOX17</italic> emerged as early as day 2 (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D). Next, we compared the relative abundance between F2L6.13- and F7L6.13-treated cells during differentiation to understand the identity of differentially regulated cell populations between the two treatments. Lateral mesoderm subpopulations (Lm1 and Lm2; defined by <italic>HAND1</italic>, <italic>ISL1</italic>, and <italic>LRRC32</italic> expression) were significantly enriched in F7L6.13- but not F2L6.13-treated hPSCs. We also found that the paraxial mesoderm subpopulations (Pm<sub>1</sub>1-3, defined by <italic>TBX6</italic>, <italic>MSGN1</italic>, <italic>DLL1</italic>, and <italic>DLL3</italic>) were equally represented in F2L6.13- and F7L6.13-treated conditions (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>E, 4F, and <xref rid="mmc1" ref-type="supplementary-material">S4</xref>C). Endoderm subpopulations (E1 and E2; defined by <italic>SOX17</italic> and <italic>FOXA2</italic>) were significantly enriched by F2L6.13 treatment. Interestingly, the endoderm lineage was preceded by a rare and distinct DKK4+/CER1+ PS subpopulation PS<sub>2</sub>1 that was only detected in F2L6.13- but not F7L6.13-treated cells (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>E, <xref rid="mmc1" ref-type="supplementary-material">S4</xref>B, and S4C). This is in agreement with the finding that F2L6.13 treatment significantly increased <italic>NODAL</italic> expression after 2&#x000a0;days of treatment when compared to F7L6.13 treatment (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>G). In addition, pluripotent cell state markers and early PS markers were also significantly favored by F2L6.13 treatment indicating that cells treated with F2L6.13 are slower to exit the pluripotency state when compared to F7L6.13 treatment (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>E, 4F, and <xref rid="mmc1" ref-type="supplementary-material">S4</xref>C). The kinetics difference in the lateral and paraxial mesoderm formation was further validated by qPCR analysis using specific markers (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>G).<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Single-nucleus transcriptome map of F2L6.13- and F7L6.13-induced mesoderm differentiation from hESCs</p><p>(A) Uniform manifold approximation and projection (UMAP) of integrated single-cell populations profiled over differentiation time course.</p><p>(B) UMAPs showing expression of cell-type-specific markers.</p><p>(C) Boxplots of cell-type-specific markers in F2L6.13- vs. F7L6.13-treated hESCs. Data represent sample-level average expression for each day and treatment condition. D0 samples were omitted from this analysis.</p><p>(D) Stream plot of relative abundances of each cell type as a function of time treated with F2L6.13 (left) or F7L6.13 (right). The same colors are used to indicate cell types as in (A).</p><p>(E) Differential abundance analysis between F2L6.13- and F7L6.13-treated cells represented as UMAP (<italic>left</italic>) and forest plot&#x000a0;(<italic>right</italic>). UMAP nodes represent cellular neighborhoods. Differentially abundant populations are indicated in red on forest plots (5% FDR, Wilcoxon test).</p><p>(F) Relative abundance of cell subpopulations across five differentiation days (<italic>n</italic>&#x000a0;= 2 independent differentiation experiments/time point/treatment).</p><p>(G) Time course RT-qPCR analysis of stage-specific markers including primitive streak&#x000a0;(<italic>TBXT</italic>), paraxial mesoderm (<italic>TBX6</italic> and <italic>MSGN1</italic>), lateral mesoderm (<italic>HAND1</italic> and <italic>BMP4</italic>), and endoderm (<italic>NODAL</italic>) in H1 hESCs treated with 30&#x000a0;nM of F2L6.13 or F7L6.13 for 5&#x000a0;days. Arrows indicate the day of treatment (<italic>n</italic>&#x000a0;= 4 independent differentiation experiments). Data are represented as mean&#x000a0;&#x000b1; SEM. Statistical analysis was performed using a one-way ANOVA followed by Tukey&#x02019;s <italic>post hoc</italic> test. <sup>&#x02217;</sup><italic>p</italic> &#x02264; 0.05 was considered significant.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0090">Taken together, our bulk and snRNA-seq expression analyses support the conclusion that &#x003b2;-catenin signaling activation through selective FZD7 or FZD2 activation leads&#x000a0;cells to adopt a paraxial mesoderm fate and that FZD7 activation additionally promotes lateral mesoderm specification.</p></sec><sec id="sec2.6"><title>Kinetics of Wnt signaling activation governs mesodermal fate induction</title><p id="p0095">A Wnt signaling gradient is known to modulate cell fate specification during gastrulation, but the contribution of different FZD receptors remains largely unexplored. Our snRNA-seq findings led us to hypothesize that the distinct kinetics of Wnt-&#x003b2;-catenin signaling downstream of FZD2 and FZD7 promote unique mesoderm fate specification. To test this, we examined the activation kinetics of the Wnt target gene <italic>SP5</italic> in response to F2L6.13 and F7L6.13 treatment (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Interestingly, we found that both FZD agonists caused similar steady increases in <italic>SP5</italic> expression during the early phase of treatment (days 0&#x02013;2). However, after day 2, the activation kinetics of the Wnt-&#x003b2;-catenin pathway began to diverge (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Whereas F2L6.13 treatment resulted in sustained <italic>SP5</italic> expression for 4&#x02013;5&#x000a0;days, a rapid attenuation of <italic>SP5</italic> expression was observed following 2&#x000a0;days of F7L6.13 treatment (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). CHIR99021 treatment at a high concentration (12&#x000a0;&#x003bc;M) mirrored the kinetics of F7L6.13-mediated Wnt activation (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>D).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Wnt activation kinetics dictates the fate of mesoderm differentiation</p><p>(A) Time course RT-qPCR analysis of <italic>SP5</italic> mRNA expression in H1 hESCs treated with 30&#x000a0;nM F2L6.13 and F7L6.13 for 5&#x000a0;days. Arrows indicate the day of treatment (<italic>n</italic>&#x000a0;= 4 independent differentiation experiments).</p><p>(B) Immunostaining against SOX2 and mCherry expression in the SP5-mCherry H1 hESC reporter line following 24&#x000a0;h treatment with 12&#x000a0;&#x003bc;M CHIR99021. Images are representative of two independent experiments.</p><p>(C) Heatmap of flow cytometry quantification of the percentage of SP5-mCherry-positive cells in WTC SP5-mCherry reporter line treated for 5&#x000a0;days with different doses of CHIR99021 or 30&#x000a0;nM of F2L6.13 or F7L6.13. Cells were harvested for flow cytometry every day (<italic>n</italic>&#x000a0;= 3 independent experiments).</p><p>(D) (Left) Quantification of time-lapse imaging of SP5-mCherry fluorescence intensity over 5&#x000a0;days of differentiation. (Right) Representative images of SP5-mCherry cells treated with either F2L6.13 or F7L6.13 for 5&#x000a0;days (mean&#x000a0;&#x000b1; SEM of 9 different images per treatment). Experiment was repeated twice with similar results.</p><p>(E) Diagram showing the CRISPR-Cas9 gene editing engineering of hPSC H1 chimera cell line. Using specific sgRNA, the FZD7 CRD is cut out and replaced by the FZD2 CRD domain on a FZD7 transmembrane domain creating FZD2 chimera cells (F2<sup>CRD</sup>F7<sup>TM</sup>).</p><p>(F and G) Time course RT-qPCR analysis of SP5 (F)&#x000a0;and HAND1 or TBX6 (G)&#x000a0;mRNA expression in H1 hESCs treated with F2L6.13 and F7L6.13 or F2<sup>CRD</sup>F7<sup>TM</sup> chimera cells treated with F2L6.13 for 5&#x000a0;days (<italic>n</italic>&#x000a0;= 3 independent differentiation experiments). Data are represented as mean&#x000a0;&#x000b1; SEM. Statistical analysis was performed using a one-way ANOVA followed by Tukey&#x02019;s <italic>post hoc</italic> test. <sup>&#x02217;</sup><italic>p</italic> &#x02264; 0.05 was considered significant.</p></caption><graphic xlink:href="gr5"/></fig></p><p id="p0100">To evaluate temporal Wnt pathway activity at a single-cell level, we generated a clonal WTC11 SP5-mCherry reporter cell line (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). Flow cytometry analysis indicated that all cells were SP5-mCherry+ after just one day of treatment with CHIR99021 (12&#x000a0;&#x003bc;M), F2L6.13, or F7L6.13 (30&#x000a0;nM), and this was sustained until at least day 4 (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). To directly monitor the activation kinetics in real time, we performed live-cell imaging experiments and measured SP5-mCherry intensity in individual cells. Consistent&#x000a0;with our mRNA results, F2L6.13 treatment was associated with sustained SP5 upregulation compared to F7L6.13 treatment (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D). Similar results were observed in the H1 AXIN2-Citrine reporter line (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>E).</p><p id="p0105">Next, we investigated whether lower concentrations of F2L6.13 would enhance lateral mesoderm formation by treating cells with a maximal dose of 30&#x000a0;nM F2L6.13 or F7L6.13 for 2&#x000a0;days followed by a dose-response treatment starting on day 2. Decreasing concentration of F2L6.13 showed lower Wnt activation and increased lateral formation on day 4 (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>A). Moreover, we used the Wnt-&#x003b2;-catenin inhibitor XAV939 to block F2L6.13-induced Wnt signaling after day 2 of differentiation. We found that lateral mesoderm formation was significantly enhanced in F2L6.13-treated cells reaching levels similar to F7L6.13-treated cells (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>B). No difference in paraxial mesoderm formation was observed. These results support our findings that the differences in F2L6.13- and F7L6.13-mediated differentiation are rooted in their different ability to activate Wnt-&#x003b2;-catenin signaling over time, which is known to influence cell fate determination. Interestingly, when mining our transcriptomic data, we observed that FZD7 expression decreased in F7L6.13-treated cells while FZD2 expression increased in F2L6.13-treated cells, possibly offering a mechanism underlying sustained &#x003b2;-catenin engagement by the FZD2 agonist antibody (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>C). The complete mechanisms regulating FZDs expression and activation during differentiation are therefore complex and will require further studies.</p><p id="p0110">Finally, we sought to confirm that the observed differences in signaling kinetics and cell specification outcomes following F2L6.13 and F7L6.13 treatments were a property of the activated receptor and signaling network and not due to different properties of the antibodies. To do this, we generated a chimeric receptor F2<sup>CRD</sup>F7<sup>TM</sup>&#x000a0;in which the N-terminal cysteine-rich domain (CRD) of FZD7 is replaced by the FZD2 CRD while preserving the transmembrane domain (TM) of FZD7. We used our clonal FZD2 KO H1 lines and precisely swapped the FZD7 CRD within the FZD7 open reading frame with the coding sequence of the FZD2 CRD&#x000a0;(<xref rid="fig5" ref-type="fig">Figures&#x000a0;5</xref>E and <xref rid="mmc1" ref-type="supplementary-material">S5</xref>D). F2<sup>CRD</sup>F7<sup>TM</sup> chimera line was confirmed by sequencing and flow cytometry (<xref rid="mmc1" ref-type="supplementary-material">Figures&#x000a0;S5</xref>D and S5E). Strikingly, F2<sup>CRD</sup>F7<sup>TM</sup> cells treated with F2L6.13 did not show sustained Wnt-&#x003b2;-catenin activation observed in the H1 parental cells. In contrast, F2L6.13 treatment in the F2<sup>CRD</sup>F7<sup>TM</sup> cells led to an early stimulation of the Wnt target genes <italic>SP5</italic> that was rapidly dampened, mimicking F7L6.13 stimulation in the parental cells (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F). In agreement with the observed Wnt-&#x003b2;-catenin activation kinetics, stimulation of hESCs expressing the F2<sup>CRD</sup>F7<sup>TM</sup> chimeric receptor with F2L6.13 led to robust expression of <italic>HAND1</italic> (lateral mesoderm) and to faster dampening of <italic>TBX6</italic> (paraxial mesoderm), both mimicking the response obtained following FZD7 stimulation (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G).</p><p id="p0115">Collectively, our data show that sustained Wnt pathway&#x000a0;activation downstream of the FZD2 receptor promotes paraxial mesoderm and represses lateral mesoderm. In contrast, transient activation of the Wnt-&#x003b2;-catenin pathway through the FZD7 receptor promotes the lateral mesoderm. Therefore, our results reveal that activation of different FZD-containing receptor complexes leads to distinct Wnt-&#x003b2;-catenin signaling kinetics that influences cell differentiation outcomes such as mesodermal cell fate bifurcation choices.</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0120">Wnt-&#x003b2;-catenin signaling governs mesendoderm lineage specification; however, the role of individual FZD receptors in regulating hPSC differentiation is poorly defined. Here, using selective FZD antibody agonists, we precisely controlled the activation of Wnt signaling at the receptor level during mesoderm cell fate specification and uncovered that stimulation of FZD2 and FZD7 led to different differentiation outcomes. Mechanistically, we demonstrated that stimulation of FZD2 and FZD7 activates &#x003b2;-catenin signaling with different kinetics and transcriptional changes promoting distinct mesodermal lineage bifurcation choices.</p><p id="p0125">Selective activation of FZD receptor complexes using antibody-based molecules that mimic Wnt proteins and efficiently stimulate the pathway has only recently been developed (<xref rid="bib15" ref-type="bibr">Janda et&#x000a0;al., 2017</xref>; <xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>). In previous studies, we showed that a pan-acting agonist antibody that binds to FZD1, 2, 4, 5, 7, 8, and LRP6 can induce the differentiation of hPSCs into mesoderm (<xref rid="bib41" ref-type="bibr">Tao et&#x000a0;al., 2019</xref>), whereas a selective FZD5:LRP6 agonist was shown to pattern neural progenitors into midbrain fate (<xref rid="bib46" ref-type="bibr">Yang et&#x000a0;al., 2024</xref>). A FZD7:LRP6 tetravalent antibody agonist was also shown to induce mesendodermal differentiation of hESCs (<xref rid="bib12" ref-type="bibr">Gumber et&#x000a0;al., 2020</xref>). The access to highly selective Wnt surrogates therefore provides an emerging option for optimal spatiotemporal control of Wnt-&#x003b2;-catenin signaling to enhance directed differentiation of hPSCs.</p><p id="p0130">Our transcriptomic data reveal that H1 hESCs express FZD2, FZD3, FZD5, and FZD7, consistent with findings from other studies (<xref rid="bib10" ref-type="bibr">Fernandez et&#x000a0;al., 2014</xref>). However, when examining protein levels using the selective FZD antibodies, we observed that FZD2 and FZD7 receptors are predominantly expressed at the membrane among the ten different FZDs. This discrepancy underscores the importance of assessing FZD receptor protein levels at the membrane, as they may differ from their transcriptional expression. FZD2 and FZD7 share strong sequence homology and were suggested to play redundant roles during development (<xref rid="bib33" ref-type="bibr">Sagara et&#x000a0;al., 1998</xref>; <xref rid="bib47" ref-type="bibr">Yu et&#x000a0;al., 2012</xref>). FZD7 is known to be the most abundant FZD receptor in undifferentiated hPSCs (<xref rid="bib10" ref-type="bibr">Fernandez et&#x000a0;al., 2014</xref>). Our genome-wide CRISPR screen designed to identify regulatory mechanisms of Wnt-&#x003b2;-catenin signaling during PS formation suggested a unique and non-redundant function for FZD2 and FZD7 receptors in hESCs. This also suggests that, during CHIR-driven hPSC differentiation, &#x003b2;-catenin signaling contributes to the upregulation and secretion of Wnt proteins that engage FZD2 and FZD7, consistent with the literature demonstrating a positive feedback mechanism where Wnt pathway activation enhances Wnt ligand expression (<xref rid="bib26" ref-type="bibr">Nakamura et&#x000a0;al., 2011</xref>).</p><p id="p0135">Although both <italic>AXIN2</italic> and <italic>SP5</italic> are target genes of Wnt signaling, <italic>SP5</italic> is a more robust marker for pathway activation in stem cells and provides a more accurate measure than <italic>AXIN2</italic>, which shows a transient and weaker response following Wnt3a and GSK3&#x003b2; inhibitor treatments (<xref rid="bib12" ref-type="bibr">Gumber et&#x000a0;al., 2020</xref>; <xref rid="bib14" ref-type="bibr">Huggins et&#x000a0;al., 2017</xref>; <xref rid="bib34" ref-type="bibr">S&#x000f6;derholm et&#x000a0;al., 2023</xref>). We showed that, while the Wnt target gene <italic>SP5</italic> was equally upregulated 24&#x000a0;h and 48&#x000a0;h following F2L6.13 and F7L6.13 treatments in hPSCs, F7L6.13 induced a faster exit from the pluripotency state when compared to F2L6.13. This result suggests early differences in gene expression regulation following activation of FZD2 and FZD7. Whole and single-cell transcriptomic analysis further revealed that F2L6.13 and F7L6.13 elicit distinct transcriptional responses associated with mesoderm specification. FZD7 but not FZD2 activation showed strong induction of lateral/cardiac mesoderm markers such as <italic>HAND1</italic>, <italic>ISL1</italic>, <italic>LRRC32</italic>, <italic>NKX2.5</italic>, <italic>BMP4</italic>, <italic>GATA2</italic>, and <italic>GATA3</italic> (<xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>). Our snRNA-seq data show that F2L6.13 treatment forms unique PS subtypes (Ps<sub>1</sub>3 and Ps<sub>2</sub>1) characterized by the expression of anterior PS genes such as <italic>DKK4</italic>, <italic>CER1</italic>, and <italic>FOXA2</italic>. This suggests that Ps<sub>1</sub>3 and Ps<sub>2</sub>1 cell populations might represent the anterior PS generated by F2L6.13, potentially acting as a transitional population toward paraxial mesoderm and endoderm populations while restricting lateral mesoderm formation.</p><p id="p0140">Highlighting the engagement of regulatory loops supporting lineage commitment, F2L6.13 and F7L6.13 differentially trigger the expression of distinct growth factors such as <italic>NODAL</italic> and <italic>BMP4</italic>, respectively. FZD2 activation favors endoderm and paraxial mesoderm, whereas FZD7 activation promotes paraxial and lateral mesoderm, consistent with the role of NODAL in anterior PS patterning for endoderm and the role of BMP4 in mesoderm specification (<xref rid="bib17" ref-type="bibr">Kim et&#x000a0;al., 2015</xref>). In addition, the transcriptional hierarchy of BMP4 to Wnt to NODAL is conserved in hESCs and during gastrulation (<xref rid="bib6" ref-type="bibr">Chhabra et&#x000a0;al., 2019</xref>; <xref rid="bib22" ref-type="bibr">Martyn et&#x000a0;al., 2018</xref>). Practically, BMP4 has been harnessed to form posterior PS-like cells and induce lateral plate mesoderm patterning and cardiac mesoderm differentiation (<xref rid="bib31" ref-type="bibr">Rojas et&#x000a0;al., 2005</xref>; <xref rid="bib42" ref-type="bibr">Tsaytler et&#x000a0;al., 2023</xref>) while Activin/NODAL pathway maintains pluripotency and drives definitive endoderm specification (<xref rid="bib3" ref-type="bibr">Brown et&#x000a0;al., 2011</xref>; <xref rid="bib28" ref-type="bibr">Osnato et&#x000a0;al., 2021</xref>).</p><p id="p0145">Wnt-&#x003b2;-catenin signaling dynamics vary dramatically in response to Wnt ligands depending on contextual factors such as the stage of differentiation or the cell type (<xref rid="bib23" ref-type="bibr">Massey et&#x000a0;al., 2019</xref>). A precise Wnt gradient governs the anteroposterior patterning of PS (anterior vs. posterior PS) and mesoderm specification (paraxial vs. lateral/cardiac mesoderm) (<xref rid="bib43" ref-type="bibr">Wu et&#x000a0;al., 2024</xref>; <xref rid="bib48" ref-type="bibr">Zhao et&#x000a0;al., 2019</xref>). We showed that, although activation of FZD2 and FZD7 leads to similar levels of early &#x003b2;-catenin target gene activation, the kinetics of activation differs between the two receptors and correlates with the observed differentiation outcomes. The robust and strong activation of Wnt signaling obtained using high doses of CHIR00921 treatment (higher than 6&#x000a0;&#x003bc;M) followed by the use of Wnt inhibitors such as the porcupine inhibitor (IWP2) is commonly used to generate cardiac mesoderm differentiation (<xref rid="bib19" ref-type="bibr">Lian et&#x000a0;al., 2013</xref>). We observed that FZD7 activation stimulates a strong early phase of Wnt-&#x003b2;-catenin activation that is inhibited on its own within 48&#x000a0;h similar to what is observed following treatment with 12&#x000a0;&#x003bc;M of CHIR99021. In contrast, FZD2 activation led to sustained activation kinetics compared to FZD7 activation or CHIR99021-mediated &#x003b2;-catenin signaling. This sustained activation of Wnt target genes is also associated with a slower emergence of paraxial mesoderm while lateral mesoderm is blocked. It has been shown that the continuous expression of <italic>TBX6</italic> can suppress cardiac differentiation and induce paraxial mesoderm and somite lineage specification (<xref rid="bib32" ref-type="bibr">Sadahiro et&#x000a0;al., 2018</xref>). <italic>TBX6</italic> and <italic>MGSN1</italic> expression slowly and continuously increase in F2L6.13-treated cells whereas F7L6.13 treatment is faster in increasing <italic>TBX6</italic> expression. This kinetics profile is in correlation with a slower exit of pluripotency induced by the FZD2 antibody agonist.</p><p id="p0150">One important question raised by our findings is how activation of two structurally related receptors (FZD2 and FZD7) leads to distinct &#x003b2;-catenin activation profiles. Our results demonstrate that the kinetics of &#x003b2;-catenin transcriptional activity differs following activation of FZD2 and FZD7. Mechanistically how this is achieved remains to be determined but could be a result of different rates of receptor endocytosis or recycling to the plasma membrane or ligand-dependent receptor degradation leading to dampening of the response. Alternatively, these receptors could localize to different plasma membrane subdomains, interact with different effectors, or transit to separate endocytic routes influencing the extent of &#x003b2;-catenin stabilization. Importantly, these differences are intrinsic to the individual FZD receptors, and not a property of the ligand, since swapping the CRD of FZD7 for the CRD of FZD2 was found to change &#x003b2;-catenin activation kinetics in response to the FZD2 antibody agonist F2L6.13 when compared to wild-type cells.</p><p id="p0155">Altogether, our work uncovered that activation of FZD2 and FZD7 in hES cells leads to distinct kinetics of &#x000df;-catenin-mediated transcriptional response that influences cell differentiation. Given the complex network of 19 Wnt and 10 FZD receptors, these differences are likely to pervasively influence lineage commitment during development and tissue homeostasis. This therefore constitutes a previously underappreciated layer of regulation in addition to the spatiotemporal control of Wnt proteins and FZD receptor expression. Whether these differences in &#x003b2;-catenin activation kinetics play important roles <italic>in&#x000a0;vivo</italic> remains to be determined but could, as we demonstrated, be leveraged to improve directed differentiation of hPSCs into more homogenous or functional cell types.</p></sec><sec id="sec4"><title>Experimental procedures</title><p id="p0160">For additional information, see <xref rid="mmc1" ref-type="supplementary-material">supplemental experimental procedures</xref>.</p><sec id="sec4.1"><title>Maintenance of hPSCs</title><p id="p0165">The hPSC line H1 hESCs (male) were obtained from the WiCell Research Institute (WAe001-A). WTC11 hiPSC line (male) was obtained from the Conklin Lab at Gladstone Institutes, UCSF (UCSFi001-A). H1 hESCs and WTC11 hiPSCs were cultured on Geltrex-coated plates in a StemFlex basal medium. hPSCs were maintained and expanded using established procedures and detailed in the supplemental information.</p></sec><sec id="sec4.2"><title>Cell differentiation</title><p id="p0170">hPSCs were differentiated into mesoderm and downstream lineages as previously described (<xref rid="bib21" ref-type="bibr">Loh et&#x000a0;al., 2016</xref>). Alternatively, mesoderm differentiation was also examined in response to only Wnt activation in the absence of any external cues using specific concentrations of CHIR99021 or FLAg molecules every 2&#x000a0;days for 5&#x000a0;days total.</p></sec><sec id="sec4.3"><title>Generation of cell lines</title><sec id="sec4.3.1"><title>H1 <italic>AXIN2</italic>-Citrine reporter cell line</title><p id="p0175">H1 iCas9 <italic>AXIN2</italic>-Citrine reporter hESC line was generated by replacing the first exon of <italic>AXIN2</italic> with a cDNA coding for histone H2B fused to the Citrine fluorescent protein into H1 hESCs that were previously engineered to express doxycycline-inducible Cas9 (see <xref rid="app2" ref-type="sec">supplemental information</xref>, <xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>).</p></sec><sec id="sec4.3.2"><title>WTC11 SP5 reporter cell line</title><p id="p0180">The pGTag-NLS-eGFP-SV40 vector (Addgene #117811) was adapted to apply the GeneWeld method (<xref rid="bib49" ref-type="bibr">Wierson et al., 2020</xref>) for generating the SP5-2A-mCherry reporter allele using the H1 hESCs. The knockin vector contains a 2A-mCherry reporter cassette, a puromycin selection marker, and <italic>LoxP</italic> sites for marker removal. The vector also features universal sgRNA sites for Cas9-induced double-strand breaks, releasing the knockin sequence for integration. Electroporation was used to deliver the CRISPR components, and cells were selected with puromycin before isolating monoclonal lines, with the undifferentiated state confirmed by OCT4 and SOX2 staining (see <xref rid="app2" ref-type="sec">supplemental information</xref>, <xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>).</p></sec><sec id="sec4.3.3"><title>F2<sup>CRD</sup>F7<sup>TM</sup> chimera line</title><p id="p0185">FZD7 CRD was replaced by FZD2 CRD using the GeneWeld CRISPR-Cas9 knockin strategy. Two sgRNAs were designed to induce double-strand breaks enabling the removal of the FZD7 CRD. A donor vector,&#x000a0;containing an FZD2 CRD with 48&#x000a0;bp homology arms, was designed with silent mutations to prevent further cleavage by Cas9. H1 hESCs FZD2 KO cells were transfected with the donor vector and universal sgRNAs to facilitate the integration of FZD2 CRD on the FZD7 receptor. Cells were sorted by fluorescence-activated cell sorting (FACS), and genotyping confirmed correct integration. The undifferentiated state was validated by OCT4 and SOX2 staining (see <xref rid="app2" ref-type="sec">supplemental information</xref>, <xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>).</p></sec></sec><sec id="sec4.4"><title>CRISPR-Cas9 screen</title><p id="p0190">H1 iCas9 <italic>AXIN2</italic>-Citrine cells were infected with the TKOv3 sgRNA library (Addgene #90924) at an MOI of 0.3, with 400-fold coverage. After 48&#x000a0;h of puromycin selection, cells were treated with doxycycline and split into 3 biological replicates, each treated with 3&#x000a0;&#x003bc;M of CHIR99021, and then sorted by citrine expression (top and bottom 15%) using FACS. Genomic DNA was extracted, sequenced, and analyzed for sgRNA representation. Hits were ranked by false discovery rate (FDR), and KEGG pathway enrichment was performed on top and bottom 15% gene hits (see <xref rid="app2" ref-type="sec">supplemental information</xref>, <xref rid="mmc2" ref-type="supplementary-material">Table&#x000a0;S1</xref>).</p></sec><sec id="sec4.5"><title>Flow cytometry</title><p id="p0195">Cells were harvested and stained with viability dyes or antibodies (<xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>) and then fixed before being run on the CytoFLEX S flow cytometer. Flow cytometry data were analyzed using the FlowJo software (see <xref rid="app2" ref-type="sec">supplemental information</xref>).</p></sec><sec id="sec4.6"><title>Bulk RNA sequencing and snRNA-seq analysis</title><p id="p0200">See <xref rid="app2" ref-type="sec">supplemental information</xref> for processing and analysis methods.</p></sec><sec id="sec4.7"><title>Immunofluorescence</title><p id="p0205">H1 hESCs treated with FLAgs and CHIR99021 were fixed, permeabilized, and blocked before incubation with primary antibodies (<xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>) and Alexa Fluor-labeled secondary antibodies. Cells were then imaged on a Zeiss LSM700 confocal microscope, and images were processed using ImageJ and Photoshop (see <xref rid="mmc1" ref-type="supplementary-material">supplemental experimental procedures</xref>).</p></sec><sec id="sec4.8"><title>Reverse-transcription PCR</title><p id="p0210">Detailed methods, including primer sequences, can be found in the supplemental information as well as <xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>.</p></sec><sec id="sec4.9"><title>Statistics</title><p id="p0215">Statistical analyses were performed with the Prism 8 software (GraphPad, San Diego, CA, USA). The number of independent experiments is indicated in the figure legends. Graphs represent the mean&#x000a0;&#x000b1; SEM. Statistical significance was determined using a two-tailed Student&#x02019;s t test to compare the means of two groups or a one-way ANOVA followed by <italic>post hoc</italic> Tukey&#x02019;s multiple comparisons test to compare different groups with one variable. <sup>&#x02217;</sup><italic>p</italic> &#x02264; 0.05 was considered significant.</p></sec></sec><sec id="sec5"><title>Resource availability</title><sec id="sec5.1"><title>Lead contact</title><p id="p0220">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead author, Stephane Angers (<email>stephane.angers@utoronto.ca</email>).</p></sec><sec id="sec5.2"><title>Materials availability</title><p id="p0225">Cell lines generated in this study are available from the <xref rid="sec5.1" ref-type="sec">lead contact</xref> upon request.</p></sec><sec sec-type="data-availability" id="sec5.3"><title>Data and code availability</title><p id="p0230">The accession number for the RNA-seq data reported in this paper is deposited at the Gene Expression Omnibus (GEO) Database: <ext-link ext-link-type="NCBI:geo" xlink:href="GSE267334" id="intref0015">GSE267334</ext-link> and the snRNA-seq data is deposited to Figshare: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.27228831.v1" id="intref0020">https://doi.org/10.6084/m9.figshare.27228831.v1</ext-link>.</p></sec></sec><sec id="sec6"><title>Acknowledgments</title><p id="p0235">The Center for Pharmaceutical Oncology provided the support and instruments that were used in these experiments. We also thank the Temerty Faculty of Medicine flow cytometry facility for assisting us with cell sorting experiments. We would also like to thank all members of the Angers labs for helpful discussion throughout this study. This work was supported by the <funding-source id="gs1">University of Toronto Medicine by Design program</funding-source> (<award-id award-type="grant" rid="gs1">MBDC2-2019-03</award-id> to J.M. and S.A.), which receives funding from the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100010785</institution-id><institution>Canada First Research Excellence Fund</institution></institution-wrap></funding-source>.&#x000a0;<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E and the graphical abstract were created with <ext-link ext-link-type="uri" xlink:href="http://Biorender.com" id="intref0025">Biorender.com</ext-link>.</p></sec><sec id="sec7"><title>Author contributions</title><p id="p0240">Conceptualization, R.C. and S.A.; methodology, R.C., A.Y., E.K., N.M., H.H., M.P.A., P.E.T., S.L., J.M., and S.A.; formal analysis, R.C., A.Y., E.K., N.M., H.H., and S.A.; investigation, R.C., A.Y., E.K., N.M., H.H., M.P.A., and G.M.; resources, J.-P.G., J.M., and S.A.; writing&#x000a0;&#x02013; original draft, R.C.; writing&#x000a0;&#x02013; review and editing, R.C., A.Y., N.M., P.E.T., G.M., and S.A.; funding acquisition and supervision, J.M. and S.A.</p></sec><sec sec-type="COI-statement" id="sec8"><title>Declaration of interests</title><p id="p0245">S.A. is an inventor on patents for the antibodies described in the manuscript.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>L.T.</given-names></name><name><surname>Nguyen</surname><given-names>A.T.</given-names></name><name><surname>Liu</surname><given-names>K.J.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Curtis</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>R.M.</given-names></name><name><surname>Raftry</surname><given-names>B.C.</given-names></name><name><surname>Ng</surname><given-names>C.Y.</given-names></name><name><surname>Vogel</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Generating human artery and vein cells from pluripotent stem cells highlights the arterial tropism of Nipah and Hendra viruses</article-title><source>Cell</source><volume>185</volume><year>2022</year><fpage>2523</fpage><lpage>2541.e30</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.05.024</pub-id><pub-id pub-id-type="pmid">35738284</pub-id>
</element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Biechele</surname><given-names>T.L.</given-names></name><name><surname>Moon</surname><given-names>R.T.</given-names></name></person-group><article-title>Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs</article-title><source>Methods Mol. Biol.</source><volume>468</volume><year>2008</year><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-249-6_8</pub-id><pub-id pub-id-type="pmid">19099249</pub-id>
</element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>S.</given-names></name><name><surname>Teo</surname><given-names>A.</given-names></name><name><surname>Pauklin</surname><given-names>S.</given-names></name><name><surname>Hannan</surname><given-names>N.</given-names></name><name><surname>Cho</surname><given-names>C.H.-H.</given-names></name><name><surname>Lim</surname><given-names>B.</given-names></name><name><surname>Vardy</surname><given-names>L.</given-names></name><name><surname>Dunn</surname><given-names>N.R.</given-names></name><name><surname>Trotter</surname><given-names>M.</given-names></name><name><surname>Pedersen</surname><given-names>R.</given-names></name><name><surname>Vallier</surname><given-names>L.</given-names></name></person-group><article-title>Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors</article-title><source>Stem Cell.</source><volume>29</volume><year>2011</year><fpage>1176</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1002/stem.666</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Chalamalasetty</surname><given-names>R.B.</given-names></name><name><surname>Dunty</surname><given-names>W.C.</given-names><suffix>Jr.</suffix></name><name><surname>Biris</surname><given-names>K.K.</given-names></name><name><surname>Ajima</surname><given-names>R.</given-names></name><name><surname>Iacovino</surname><given-names>M.</given-names></name><name><surname>Beisaw</surname><given-names>A.</given-names></name><name><surname>Feigenbaum</surname><given-names>L.</given-names></name><name><surname>Chapman</surname><given-names>D.L.</given-names></name><name><surname>Yoon</surname><given-names>J.K.</given-names></name><name><surname>Kyba</surname><given-names>M.</given-names></name><name><surname>Yamaguchi</surname><given-names>T.P.</given-names></name></person-group><article-title>The Wnt3a/&#x003b2;-catenin target gene Mesogenin1 controls the segmentation clock by activating a Notch signalling program</article-title><source>Nat. Commun.</source><volume>2</volume><year>2011</year><fpage>390</fpage><pub-id pub-id-type="doi">10.1038/ncomms1381</pub-id><pub-id pub-id-type="pmid">21750544</pub-id>
</element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Ouyang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Bhatia</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>S.-J.</given-names></name><name><surname>Shah</surname><given-names>D.</given-names></name><name><surname>Sura</surname><given-names>A.</given-names></name><name><surname>Yeh</surname><given-names>W.-C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Development of potent, selective surrogate WNT molecules and their application in defining frizzled requirements</article-title><source>Cell Chem. Biol.</source><volume>27</volume><year>2020</year><fpage>598</fpage><lpage>609.e4</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2020.02.009</pub-id><pub-id pub-id-type="pmid">32220333</pub-id>
</element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Chhabra</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Goh</surname><given-names>R.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Warmflash</surname><given-names>A.</given-names></name></person-group><article-title>Dissecting the dynamics of signaling events in the BMP, WNT, and NODAL cascade during self-organized fate patterning in human gastruloids</article-title><source>PLoS Biol.</source><volume>17</volume><year>2019</year><object-id pub-id-type="publisher-id">e3000498</object-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000498</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Chidiac</surname><given-names>R.</given-names></name><name><surname>Angers</surname><given-names>S.</given-names></name></person-group><article-title>Wnt signaling in stem cells during development and cell lineage specification</article-title><source>Curr. Top. Dev. Biol.</source><volume>153</volume><year>2023</year><fpage>121</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/bs.ctdb.2023.01.005</pub-id><pub-id pub-id-type="pmid">36967192</pub-id>
</element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chidiac</surname><given-names>R.</given-names></name><name><surname>Abedin</surname><given-names>M.</given-names></name><name><surname>Macleod</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Thibeault</surname><given-names>P.E.</given-names></name><name><surname>Blazer</surname><given-names>L.L.</given-names></name><name><surname>Adams</surname><given-names>J.J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Roehrich</surname><given-names>H.</given-names></name><name><surname>Jo</surname><given-names>H.-N.</given-names></name><etal/></person-group><article-title>A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy</article-title><source>EMBO Mol. Med.</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">e13977</object-id><pub-id pub-id-type="doi">10.15252/emmm.202113977</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>D.E.</given-names></name><name><surname>Melton</surname><given-names>D.</given-names></name></person-group><article-title>Turning straw into gold: directing cell fate for regenerative medicine</article-title><source>Nat. Rev. Genet.</source><volume>12</volume><year>2011</year><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/nrg2938</pub-id><pub-id pub-id-type="pmid">21386864</pub-id>
</element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>A.</given-names></name><name><surname>Huggins</surname><given-names>I.J.</given-names></name><name><surname>Perna</surname><given-names>L.</given-names></name><name><surname>Brafman</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Yao</surname><given-names>S.</given-names></name><name><surname>Gaasterland</surname><given-names>T.</given-names></name><name><surname>Carson</surname><given-names>D.A.</given-names></name><name><surname>Willert</surname><given-names>K.</given-names></name></person-group><article-title>The WNT receptor FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>111</volume><year>2014</year><fpage>1409</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1073/pnas.1323697111</pub-id><pub-id pub-id-type="pmid">24474766</pub-id>
</element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>J.L.</given-names></name><name><surname>Ang</surname><given-names>L.T.</given-names></name><name><surname>Loh</surname><given-names>K.M.</given-names></name></person-group><article-title>A critical look: Challenges in differentiating human pluripotent stem cells into desired cell types and organoids</article-title><source>Wiley Interdiscip. Rev. Dev. Biol.</source><volume>9</volume><year>2020</year><fpage>e368</fpage><pub-id pub-id-type="doi">10.1002/wdev.368</pub-id><pub-id pub-id-type="pmid">31746148</pub-id>
</element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Gumber</surname><given-names>D.</given-names></name><name><surname>Do</surname><given-names>M.</given-names></name><name><surname>Suresh Kumar</surname><given-names>N.</given-names></name><name><surname>Sonavane</surname><given-names>P.R.</given-names></name><name><surname>Wu</surname><given-names>C.C.N.</given-names></name><name><surname>Cruz</surname><given-names>L.S.</given-names></name><name><surname>Grainger</surname><given-names>S.</given-names></name><name><surname>Carson</surname><given-names>D.</given-names></name><name><surname>Gaasterland</surname><given-names>T.</given-names></name><name><surname>Willert</surname><given-names>K.</given-names></name></person-group><article-title>Selective activation of FZD7 promotes mesendodermal differentiation of human pluripotent stem cells</article-title><source>Elife</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">e63060</object-id><pub-id pub-id-type="doi">10.7554/eLife.63060</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Bian</surname><given-names>Y.</given-names></name><name><surname>Poddar</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>McGaughey</surname><given-names>J.</given-names></name><name><surname>Bell</surname><given-names>A.</given-names></name><name><surname>Blazer</surname><given-names>L.L.</given-names></name><name><surname>Adams</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Single-cell spatial transcriptomics reveals a dynamic control of metabolic zonation and liver regeneration by endothelial cell Wnt2 and Wnt9b</article-title><source>Cell Rep. Med.</source><volume>3</volume><year>2022</year><object-id pub-id-type="publisher-id">100754</object-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100754</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Huggins</surname><given-names>I.J.</given-names></name><name><surname>Bos</surname><given-names>T.</given-names></name><name><surname>Gaylord</surname><given-names>O.</given-names></name><name><surname>Jessen</surname><given-names>C.</given-names></name><name><surname>Lonquich</surname><given-names>B.</given-names></name><name><surname>Puranen</surname><given-names>A.</given-names></name><name><surname>Richter</surname><given-names>J.</given-names></name><name><surname>Rossdam</surname><given-names>C.</given-names></name><name><surname>Brafman</surname><given-names>D.</given-names></name><name><surname>Gaasterland</surname><given-names>T.</given-names></name><name><surname>Willert</surname><given-names>K.</given-names></name></person-group><article-title>The WNT target SP5 negatively regulates WNT transcriptional programs in human pluripotent stem cells</article-title><source>Nat. Commun.</source><volume>8</volume><year>2017</year><fpage>1034</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01203-1</pub-id><pub-id pub-id-type="pmid">29044119</pub-id>
</element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Janda</surname><given-names>C.Y.</given-names></name><name><surname>Dang</surname><given-names>L.T.</given-names></name><name><surname>You</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>de Lau</surname><given-names>W.</given-names></name><name><surname>Zhong</surname><given-names>Z.A.</given-names></name><name><surname>Yan</surname><given-names>K.S.</given-names></name><name><surname>Marecic</surname><given-names>O.</given-names></name><name><surname>Siepe</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Surrogate Wnt agonists that phenocopy canonical Wnt and &#x003b2;-catenin signalling</article-title><source>Nature</source><volume>545</volume><year>2017</year><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1038/nature22306</pub-id><pub-id pub-id-type="pmid">28467818</pub-id>
</element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Kattman</surname><given-names>S.J.</given-names></name><name><surname>Witty</surname><given-names>A.D.</given-names></name><name><surname>Gagliardi</surname><given-names>M.</given-names></name><name><surname>Dubois</surname><given-names>N.C.</given-names></name><name><surname>Niapour</surname><given-names>M.</given-names></name><name><surname>Hotta</surname><given-names>A.</given-names></name><name><surname>Ellis</surname><given-names>J.</given-names></name><name><surname>Keller</surname><given-names>G.</given-names></name></person-group><article-title>Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines</article-title><source>Cell Stem Cell</source><volume>8</volume><year>2011</year><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.12.008</pub-id><pub-id pub-id-type="pmid">21295278</pub-id>
</element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.-S.</given-names></name><name><surname>Horst</surname><given-names>A.</given-names></name><name><surname>Blinka</surname><given-names>S.</given-names></name><name><surname>Stamm</surname><given-names>K.</given-names></name><name><surname>Mahnke</surname><given-names>D.</given-names></name><name><surname>Schuman</surname><given-names>J.</given-names></name><name><surname>Gundry</surname><given-names>R.</given-names></name><name><surname>Tomita-Mitchell</surname><given-names>A.</given-names></name><name><surname>Lough</surname><given-names>J.</given-names></name></person-group><article-title>Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis</article-title><source>PLoS One</source><volume>10</volume><year>2015</year><object-id pub-id-type="publisher-id">e0118670</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0118670</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Kispert</surname><given-names>A.</given-names></name><name><surname>Herrmann</surname><given-names>B.G.</given-names></name></person-group><article-title>Immunohistochemical analysis of the Brachyury protein in wild-type and mutant mouse embryos</article-title><source>Dev. Biol.</source><volume>161</volume><year>1994</year><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1006/dbio.1994.1019</pub-id><pub-id pub-id-type="pmid">8293872</pub-id>
</element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Azarin</surname><given-names>S.M.</given-names></name><name><surname>Zhu</surname><given-names>K.</given-names></name><name><surname>Hazeltine</surname><given-names>L.B.</given-names></name><name><surname>Bao</surname><given-names>X.</given-names></name><name><surname>Hsiao</surname><given-names>C.</given-names></name><name><surname>Kamp</surname><given-names>T.J.</given-names></name><name><surname>Palecek</surname><given-names>S.P.</given-names></name></person-group><article-title>Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/&#x003b2;-catenin signaling under fully defined conditions</article-title><source>Nat. Protoc.</source><volume>8</volume><year>2013</year><fpage>162</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.150</pub-id><pub-id pub-id-type="pmid">23257984</pub-id>
</element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>K.M.</given-names></name><name><surname>Ang</surname><given-names>L.T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Ang</surname><given-names>J.</given-names></name><name><surname>Auyeong</surname><given-names>J.Q.</given-names></name><name><surname>Lee</surname><given-names>K.L.</given-names></name><name><surname>Choo</surname><given-names>S.H.</given-names></name><name><surname>Lim</surname><given-names>C.Y.Y.</given-names></name><name><surname>Nichane</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficient endoderm induction from human pluripotent stem cells by logically directing signals controlling lineage bifurcations</article-title><source>Cell Stem Cell</source><volume>14</volume><year>2014</year><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.12.007</pub-id><pub-id pub-id-type="pmid">24412311</pub-id>
</element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>K.M.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Koh</surname><given-names>P.W.</given-names></name><name><surname>Deng</surname><given-names>T.Z.</given-names></name><name><surname>Sinha</surname><given-names>R.</given-names></name><name><surname>Tsai</surname><given-names>J.M.</given-names></name><name><surname>Barkal</surname><given-names>A.A.</given-names></name><name><surname>Shen</surname><given-names>K.Y.</given-names></name><name><surname>Jain</surname><given-names>R.</given-names></name><name><surname>Morganti</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types</article-title><source>Cell</source><volume>166</volume><year>2016</year><fpage>451</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.011</pub-id><pub-id pub-id-type="pmid">27419872</pub-id>
</element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Martyn</surname><given-names>I.</given-names></name><name><surname>Kanno</surname><given-names>T.Y.</given-names></name><name><surname>Ruzo</surname><given-names>A.</given-names></name><name><surname>Siggia</surname><given-names>E.D.</given-names></name><name><surname>Brivanlou</surname><given-names>A.H.</given-names></name></person-group><article-title>Self-organization of a human organizer by combined Wnt and Nodal signalling</article-title><source>Nature</source><volume>558</volume><year>2018</year><fpage>132</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0150-y</pub-id><pub-id pub-id-type="pmid">29795348</pub-id>
</element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Massey</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Alvarenga</surname><given-names>O.</given-names></name><name><surname>Saez</surname><given-names>T.</given-names></name><name><surname>Schmerer</surname><given-names>M.</given-names></name><name><surname>Warmflash</surname><given-names>A.</given-names></name></person-group><article-title>Synergy with TGF&#x003b2; ligands switches WNT pathway dynamics from transient to sustained during human pluripotent cell differentiation</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>116</volume><year>2019</year><fpage>4989</fpage><lpage>4998</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815363116</pub-id><pub-id pub-id-type="pmid">30819898</pub-id>
</element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>C.E.</given-names></name><name><surname>Keller</surname><given-names>G.</given-names></name></person-group><article-title>Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development</article-title><source>Cell</source><volume>132</volume><year>2008</year><fpage>661</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.02.008</pub-id><pub-id pub-id-type="pmid">18295582</pub-id>
</element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Nabhan</surname><given-names>A.N.</given-names></name><name><surname>Webster</surname><given-names>J.D.</given-names></name><name><surname>Adams</surname><given-names>J.J.</given-names></name><name><surname>Blazer</surname><given-names>L.</given-names></name><name><surname>Everrett</surname><given-names>C.</given-names></name><name><surname>Eidenschenk</surname><given-names>C.</given-names></name><name><surname>Arlantico</surname><given-names>A.</given-names></name><name><surname>Fleming</surname><given-names>I.</given-names></name><name><surname>Brightbill</surname><given-names>H.D.</given-names></name><name><surname>Wolters</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Targeted alveolar regeneration with Frizzled-specific agonists</article-title><source>Cell</source><volume>186</volume><year>2023</year><fpage>2995</fpage><lpage>3012.e15</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.05.022</pub-id><pub-id pub-id-type="pmid">37321220</pub-id>
</element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Tsiairis</surname><given-names>C.D.</given-names></name><name><surname>&#x000d6;zbek</surname><given-names>S.</given-names></name><name><surname>Holstein</surname><given-names>T.W.</given-names></name></person-group><article-title>Autoregulatory and repressive inputs localize Hydra Wnt3 to the head organizer</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>108</volume><year>2011</year><fpage>9137</fpage><lpage>9142</lpage><pub-id pub-id-type="doi">10.1073/pnas.1018109108</pub-id><pub-id pub-id-type="pmid">21576458</pub-id>
</element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Nostro</surname><given-names>M.C.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Keller</surname><given-names>G.M.</given-names></name><name><surname>Gadue</surname><given-names>P.</given-names></name></person-group><article-title>Wnt, activin, and BMP signaling regulate distinct stages in the developmental pathway from embryonic stem cells to blood</article-title><source>Cell Stem Cell</source><volume>2</volume><year>2008</year><fpage>60</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.10.011</pub-id><pub-id pub-id-type="pmid">18371422</pub-id>
</element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Osnato</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>S.</given-names></name><name><surname>Krueger</surname><given-names>C.</given-names></name><name><surname>Andrews</surname><given-names>S.</given-names></name><name><surname>Collier</surname><given-names>A.J.</given-names></name><name><surname>Nakanoh</surname><given-names>S.</given-names></name><name><surname>Quiroga Londo&#x000f1;o</surname><given-names>M.</given-names></name><name><surname>Wesley</surname><given-names>B.T.</given-names></name><name><surname>Muraro</surname><given-names>D.</given-names></name><name><surname>Brumm</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>TGF&#x003b2; signalling is required to maintain pluripotency of human na&#x000ef;ve pluripotent stem cells</article-title><source>Elife</source><volume>10</volume><year>2021</year><object-id pub-id-type="publisher-id">e67259</object-id><pub-id pub-id-type="doi">10.7554/eLife.67259</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Pavlovic</surname><given-names>Z.</given-names></name><name><surname>Adams</surname><given-names>J.J.</given-names></name><name><surname>Blazer</surname><given-names>L.L.</given-names></name><name><surname>Gakhal</surname><given-names>A.K.</given-names></name><name><surname>Jarvik</surname><given-names>N.</given-names></name><name><surname>Steinhart</surname><given-names>Z.</given-names></name><name><surname>Robitaille</surname><given-names>M.</given-names></name><name><surname>Mascall</surname><given-names>K.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Angers</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties</article-title><source>mAbs</source><volume>10</volume><year>2018</year><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1080/19420862.2018.1515565</pub-id><pub-id pub-id-type="pmid">30183492</pub-id>
</element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>J.</given-names></name><name><surname>Pfeiffer</surname><given-names>M.J.</given-names></name><name><surname>Frank</surname><given-names>S.</given-names></name><name><surname>Adachi</surname><given-names>K.</given-names></name><name><surname>Piccini</surname><given-names>I.</given-names></name><name><surname>Quaranta</surname><given-names>R.</given-names></name><name><surname>Ara&#x000fa;zo-Bravo</surname><given-names>M.</given-names></name><name><surname>Schwarz</surname><given-names>J.</given-names></name><name><surname>Schade</surname><given-names>D.</given-names></name><name><surname>Leidel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Stepwise clearance of repressive roadblocks drives cardiac induction in human ESCs</article-title><source>Cell Stem Cell</source><volume>18</volume><year>2016</year><fpage>554</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.03.008</pub-id><pub-id pub-id-type="pmid">27058939</pub-id>
</element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>A.</given-names></name><name><surname>De Val</surname><given-names>S.</given-names></name><name><surname>Heidt</surname><given-names>A.B.</given-names></name><name><surname>Xu</surname><given-names>S.-M.</given-names></name><name><surname>Bristow</surname><given-names>J.</given-names></name><name><surname>Black</surname><given-names>B.L.</given-names></name></person-group><article-title>Gata4 expression in lateral mesoderm is downstream of BMP4 and is activated directly by Forkhead and GATA transcription factors through a distal enhancer element</article-title><source>Development</source><volume>132</volume><year>2005</year><fpage>3405</fpage><lpage>3417</lpage><pub-id pub-id-type="doi">10.1242/dev.01913</pub-id><pub-id pub-id-type="pmid">15987774</pub-id>
</element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Sadahiro</surname><given-names>T.</given-names></name><name><surname>Isomi</surname><given-names>M.</given-names></name><name><surname>Muraoka</surname><given-names>N.</given-names></name><name><surname>Kojima</surname><given-names>H.</given-names></name><name><surname>Haginiwa</surname><given-names>S.</given-names></name><name><surname>Kurotsu</surname><given-names>S.</given-names></name><name><surname>Tamura</surname><given-names>F.</given-names></name><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Tohyama</surname><given-names>S.</given-names></name><name><surname>Fujita</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Tbx6 induces nascent mesoderm from pluripotent stem cells and temporally controls cardiac versus somite lineage diversification</article-title><source>Cell Stem Cell</source><volume>23</volume><year>2018</year><fpage>382</fpage><lpage>395.e5</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.07.001</pub-id><pub-id pub-id-type="pmid">30100166</pub-id>
</element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Sagara</surname><given-names>N.</given-names></name><name><surname>Toda</surname><given-names>G.</given-names></name><name><surname>Hirai</surname><given-names>M.</given-names></name><name><surname>Terada</surname><given-names>M.</given-names></name><name><surname>Katoh</surname><given-names>M.</given-names></name></person-group><article-title>Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>252</volume><year>1998</year><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1998.9607</pub-id><pub-id pub-id-type="pmid">9813155</pub-id>
</element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>S&#x000f6;derholm</surname><given-names>S.</given-names></name><name><surname>Jauregi-Miguel</surname><given-names>A.</given-names></name><name><surname>Pagella</surname><given-names>P.</given-names></name><name><surname>Ghezzi</surname><given-names>V.</given-names></name><name><surname>Zambanini</surname><given-names>G.</given-names></name><name><surname>Nordin</surname><given-names>A.</given-names></name><name><surname>Cant&#x000f9;</surname><given-names>C.</given-names></name></person-group><article-title>Single-cell response to Wnt signaling activation reveals uncoupling of Wnt target gene expression</article-title><source>Exp. Cell Res.</source><volume>429</volume><year>2023</year><object-id pub-id-type="publisher-id">113646</object-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2023.113646</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Solnica-Krezel</surname><given-names>L.</given-names></name><name><surname>Sepich</surname><given-names>D.S.</given-names></name></person-group><article-title>Gastrulation: making and shaping germ layers</article-title><source>Annu. Rev. Cell Dev. Biol.</source><volume>28</volume><year>2012</year><fpage>687</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154043</pub-id><pub-id pub-id-type="pmid">22804578</pub-id>
</element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Steinhart</surname><given-names>Z.</given-names></name><name><surname>Angers</surname><given-names>S.</given-names></name></person-group><article-title>Wnt signaling in development and tissue homeostasis</article-title><source>Development</source><volume>145</volume><year>2018</year><object-id pub-id-type="publisher-id">dev146589</object-id><pub-id pub-id-type="doi">10.1242/dev.146589</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Steinhart</surname><given-names>Z.</given-names></name><name><surname>Pavlovic</surname><given-names>Z.</given-names></name><name><surname>Chandrashekhar</surname><given-names>M.</given-names></name><name><surname>Hart</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Robitaille</surname><given-names>M.</given-names></name><name><surname>Brown</surname><given-names>K.R.</given-names></name><name><surname>Jaksani</surname><given-names>S.</given-names></name><name><surname>Overmeer</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Genome-wide CRISPR screens reveal a Wnt&#x02013;FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors</article-title><source>Nat. Med.</source><volume>23</volume><year>2017</year><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nm.4219</pub-id><pub-id pub-id-type="pmid">27869803</pub-id>
</element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Sumi</surname><given-names>T.</given-names></name><name><surname>Tsuneyoshi</surname><given-names>N.</given-names></name><name><surname>Nakatsuji</surname><given-names>N.</given-names></name><name><surname>Suemori</surname><given-names>H.</given-names></name></person-group><article-title>Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling</article-title><source>Development</source><volume>135</volume><year>2008</year><fpage>2969</fpage><lpage>2979</lpage><pub-id pub-id-type="doi">10.1242/dev.021121</pub-id><pub-id pub-id-type="pmid">18667462</pub-id>
</element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J.Y.</given-names></name><name><surname>Sriram</surname><given-names>G.</given-names></name><name><surname>Rufaihah</surname><given-names>A.J.</given-names></name><name><surname>Neoh</surname><given-names>K.G.</given-names></name><name><surname>Cao</surname><given-names>T.</given-names></name></person-group><article-title>Efficient derivation of lateral plate and paraxial mesoderm subtypes from human embryonic stem cells through GSKi-mediated differentiation</article-title><source>Stem Cells Dev.</source><volume>22</volume><year>2013</year><fpage>1893</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1089/scd.2012.0590</pub-id><pub-id pub-id-type="pmid">23413973</pub-id>
</element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>S.</given-names></name><name><surname>Chung</surname><given-names>U.-I.</given-names></name><name><surname>Ohba</surname><given-names>S.</given-names></name><name><surname>Hojo</surname><given-names>H.</given-names></name></person-group><article-title>Understanding paraxial mesoderm development and sclerotome specification for skeletal repair</article-title><source>Exp. Mol. Med.</source><volume>52</volume><year>2020</year><fpage>1166</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1038/s12276-020-0482-1</pub-id><pub-id pub-id-type="pmid">32788657</pub-id>
</element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Mis</surname><given-names>M.</given-names></name><name><surname>Blazer</surname><given-names>L.</given-names></name><name><surname>Ustav</surname><given-names>M.</given-names><suffix>Jnr</suffix></name><name><surname>Steinhart</surname><given-names>Z.</given-names></name><name><surname>Chidiac</surname><given-names>R.</given-names></name><name><surname>Kubarakos</surname><given-names>E.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Jarvik</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice</article-title><source>Elife</source><volume>8</volume><year>2019</year><object-id pub-id-type="publisher-id">e46134</object-id><pub-id pub-id-type="doi">10.7554/eLife.46134</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Tsaytler</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Blaess</surname><given-names>G.</given-names></name><name><surname>Schifferl</surname><given-names>D.</given-names></name><name><surname>Veenvliet</surname><given-names>J.V.</given-names></name><name><surname>Wittler</surname><given-names>L.</given-names></name><name><surname>Timmermann</surname><given-names>B.</given-names></name><name><surname>Herrmann</surname><given-names>B.G.</given-names></name><name><surname>Koch</surname><given-names>F.</given-names></name></person-group><article-title>BMP4 triggers regulatory circuits specifying the cardiac mesoderm lineage</article-title><source>Development</source><volume>150</volume><year>2023</year><object-id pub-id-type="publisher-id">dev201450</object-id><pub-id pub-id-type="doi">10.1242/dev.201450</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="opteSIiBBUVvt"><person-group person-group-type="author"><name><surname>Wierson</surname><given-names>W.A.</given-names></name><name><surname>Welker</surname><given-names>J.M.</given-names></name><name><surname>Almeida</surname><given-names>M.P.</given-names></name><name><surname>Mann</surname><given-names>C.M.</given-names></name><name><surname>Webster</surname><given-names>D.A.</given-names></name><name><surname>Torrie</surname><given-names>M.E.</given-names></name><name><surname>Weiss</surname><given-names>T.J.</given-names></name><name><surname>Kambakam</surname><given-names>S.</given-names></name><name><surname>Vollbrecht</surname><given-names>M.K.</given-names></name><name><surname>Lan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficient targeted integration directed by short homology in zebrafish and mammalian cells</article-title><source>eLife</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">e53968</object-id><pub-id pub-id-type="doi">10.7554/eLife.53968</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Mizikovsky</surname><given-names>D.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Naval-Sanchez</surname><given-names>M.</given-names></name><name><surname>Tan</surname><given-names>S.Z.</given-names></name><name><surname>Alvarez</surname><given-names>Y.D.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Wnt dose escalation during the exit from pluripotency identifies tranilast as a regulator of cardiac mesoderm</article-title><source>Dev. Cell</source><volume>59</volume><year>2024</year><fpage>705</fpage><lpage>722.e8</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2024.01.019</pub-id><pub-id pub-id-type="pmid">38354738</pub-id>
</element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>P.-F.</given-names></name><name><surname>Houssin</surname><given-names>N.</given-names></name><name><surname>Ferri-Lagneau</surname><given-names>K.F.</given-names></name><name><surname>Thisse</surname><given-names>B.</given-names></name><name><surname>Thisse</surname><given-names>C.</given-names></name></person-group><article-title>Construction of a vertebrate embryo from two opposing morphogen gradients</article-title><source>Science</source><volume>344</volume><year>2014</year><fpage>87</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1126/science.1248252</pub-id><pub-id pub-id-type="pmid">24700857</pub-id>
</element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>T.P.</given-names></name><name><surname>Takada</surname><given-names>S.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>N.</given-names></name><name><surname>McMahon</surname><given-names>A.P.</given-names></name></person-group><article-title>T (Brachyury) is a direct target of Wnt3a during paraxial mesoderm specification</article-title><source>Genes Dev.</source><volume>13</volume><year>1999</year><fpage>3185</fpage><lpage>3190</lpage><pub-id pub-id-type="doi">10.1101/gad.13.24.3185</pub-id><pub-id pub-id-type="pmid">10617567</pub-id>
</element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Chidiac</surname><given-names>R.</given-names></name><name><surname>Russo</surname><given-names>E.</given-names></name><name><surname>Steenland</surname><given-names>H.</given-names></name><name><surname>Pauli</surname><given-names>Q.</given-names></name><name><surname>Bonin</surname><given-names>R.</given-names></name><name><surname>Blazer</surname><given-names>L.L.</given-names></name><name><surname>Adams</surname><given-names>J.J.</given-names></name><name><surname>Sidhu</surname><given-names>S.S.</given-names></name><name><surname>Goeva</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Exploiting spatiotemporal regulation of FZD5 during neural patterning for efficient ventral midbrain specification</article-title><source>Development</source><volume>151</volume><year>2024</year><object-id pub-id-type="publisher-id">dev202545</object-id><pub-id pub-id-type="doi">10.1242/dev.202545</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>N.</given-names></name><name><surname>Nathans</surname><given-names>J.</given-names></name></person-group><article-title>Frizzled 2 and frizzled 7 function redundantly in convergent extension and closure of the ventricular septum and palate: evidence for a network of interacting genes</article-title><source>Development</source><volume>139</volume><year>2012</year><fpage>4383</fpage><lpage>4394</lpage><pub-id pub-id-type="doi">10.1242/dev.083352</pub-id><pub-id pub-id-type="pmid">23095888</pub-id>
</element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Deciphering Role of Wnt Signalling in Cardiac Mesoderm and Cardiomyocyte Differentiation from Human iPSCs: Four-dimensional control of Wnt pathway for hiPSC-CMs differentiation</article-title><source>Sci. Rep.</source><volume>9</volume><year>2019</year><object-id pub-id-type="publisher-id">19389</object-id><pub-id pub-id-type="doi">10.1038/s41598-019-55620-x</pub-id></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0255">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures&#x000a0;S1&#x02013;S5 and supplemental experimental procedures</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2"><caption><title>Table&#x000a0;S1. CRISPR screen</title></caption><media xlink:href="mmc2.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc3"><caption><title>Table&#x000a0;S2. RNA sequencing</title></caption><media xlink:href="mmc3.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc4"><caption><title>Table&#x000a0;S3. Primer, gRNA, and antibody details</title></caption><media xlink:href="mmc4.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc5"><caption><title>Document S2. Article plus supplemental information</title></caption><media xlink:href="mmc5.pdf"/></supplementary-material>
</p></sec><fn-group><fn id="app1" fn-type="supplementary-material"><p id="p0250">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.stemcr.2024.102391" id="intref0030">https://doi.org/10.1016/j.stemcr.2024.102391</ext-link>.</p></fn></fn-group></back></article>